COMparison ofPlatelet reactivity following prAsugrel and ticagrelor loading dose inST-Segment elevation myocardial infarctIONpatients: The COMPASSION study
| Autor: | Laurent Bonello, Stephane Luigi, Anne Champenois, Franck Paganelli, Virginie Chelini, Bruno Bultez, Françoise Dignat-George, Franck Thuny, Michael Peyrol, Corinne Frere, Zair Mokrani, Mélanie Gaubert, Richard Toesca, Serge Yvorra, Jacques Bessereau, Marc Laine |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Ticagrelor medicine.medical_specialty Adenosine Prasugrel Platelet Function Tests medicine.medical_treatment Myocardial Infarction Loading dose Electrocardiography Risk Factors Internal medicine medicine Humans ST segment cardiovascular diseases Myocardial infarction Acute Coronary Syndrome Aged business.industry Percutaneous coronary intervention Hematology General Medicine Middle Aged Platelet Activation Clopidogrel medicine.disease Clinical trial Treatment Outcome Anesthesia Purinergic P2Y Receptor Antagonists Cardiology Female business Prasugrel Hydrochloride Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Platelets. 26:570-572 |
| ISSN: | 1369-1635 0953-7104 |
| DOI: | 10.3109/09537104.2014.959914 |
| Popis: | Prasugrel and ticagrelor are potent P2Y12-ADP receptor antagonists which are superior to clopidogrel in acute coronary syndromes. To date no clinical trial directly compared these two drugs. Platelet reactivity correlates with ischemic and bleeding events in patients undergoing percutaneous coronary intervention. Recent pharmacological studies have observed a delayed onset of action of these two drugs in ST-segment elevation myocardial infarction (STEMI). We provide the first adequately powered pharmacological study comparing PR following ticagrelor and prasugrel loading dose (LD) in STEMI patients when the maximal biological effect is reached. In the present study, ticagrelor was associated with a lower rate of high on-treatment PR compared to prasugrel. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|